CJC-1295 with DAC is a modified growth hormone-releasing hormone analog (tetrasubstituted GRF 1-29) conjugated to Drug Affinity Complex (DAC) via a lysine linker. CAS 863288-34-0, molecular weight ~3647 Da. The DAC moiety enables albumin binding, extending plasma half-life to approximately 6-8 days in research models. Research compound — for laboratory use only.
Compound Specifications
CJC-1295 with DAC is a modified GHRH(1-29) analog conjugated to a Drug Affinity Complex (maleimidopropionic acid–lysine linker) that enables covalent binding to serum albumin. The base peptide has CAS 863288-34-0. The DAC modification extends the half-life to approximately 6–8 days by preventing renal clearance. Molecular weight approximately 3647 Da (peptide + linker). Research compound — for laboratory use only.
Product Details
- Compound: CJC-1295 with DAC (Drug Affinity Complex)
- Purity: >99%
- Form: Lyophilized powder
- Testing: View COA (Verified by Janoshik) →
mg
📚 View Published Research on CJC-1295 with DAC →
Peer-reviewed citations from PubMed — for educational purposes only
CJC-1295 with DAC documentation path
This CJC-1295 with DAC listing is organized for analog identity, DAC albumin-binding context, and batch-documentation review. It is not intended to guide use or protocol design.
- Identity: modified GHRH(1-29) analog with Drug Affinity Complex; base peptide CAS 863288-34-0.
- Documentation: review COA records and Quality & Testing.
- Literature context: see CJC-1295 with DAC research and CJC-1295 + Ipamorelin research.
Research use only. This page does not provide dosing, administration, reconstitution, treatment, hormone-use, or human-use guidance.